Clinical research
10 clinical trial site selection experts
These ten professionals have led or carried out feasibility, site identification and site selection work for clinical trials. They can explain how countries, sites and investigators are assessed and how feasibility data is used to plan enrollment before a study starts.
Professionals to explore
01—10Daniel Young
LinkedInExperience: Director Head of Trial Feasibility & Site Identification · Daiichi Sankyo
Director Head of Trial Feasibility & Site Identification at Daiichi Sankyo since February 2024, after serving as Associate Director, Trial Feasibility & Site Identification there (2022–2024). Former Strategic Feasibility Manager at UCB (2018–2022) and Global Feasibility Analyst at Syneos Health and INC Research (2016–2018).
Erica Medlar
LinkedInExperience: Country and Site Feasibility Lead · Astellas Pharma
Country and Site Feasibility Lead at Astellas Pharma since January 2026, a role the profile describes as evaluating a trial's suitability by recommending the right countries, sites and investigators to optimize performance. Former Associate Director, Site Identification (2023–2025) and Senior Manager, Site Identification and Relationship (2022–2023) at Worldwide Clinical Trials, and Lead Feasibility Specialist at PRA Health Sciences (2016–2021).
Leanna Sauls
LinkedInExperience: Site Identification and Selection Specialist · Takeda
Former Site Identification and Selection Specialist at Takeda (2022–2026) and Manager, Feasibility there since March 2026, where the profile says the work covers data-driven feasibility assessments for Phase I–IV studies, including protocol design optimization, country and site identification, and enrollment strategy and modeling. Before Takeda, Senior Site Feasibility Specialist at IQVIA (2020–2021).
Mary Gallo
LinkedInExperience: Country and Site Feasibility Lead · Astellas Pharma
Country and Site Feasibility Lead at Astellas Pharma since October 2025. Former Senior Manager, Global Feasibility and Trial Equity (2022–2025) and Senior Manager, Study Start Up (2021–2022) at Takeda, and Associate Director, Global Feasibility, Site Patient Access at Syneos Health (2020–2021). The profile cites expertise in targeted feasibility analyses, clinical trial delivery strategies and feasibility reports.
Nadia Lim
LinkedInExperience: Head, Feasibility Strategy and Analytics (Internal Medicine, Inflammation & Immunology, Rare) · Pfizer
Head, Feasibility Strategy and Analytics (Internal Medicine, Inflammation & Immunology, Rare) at Pfizer since January 2024. Former Director, Site Inteligence SIL Group Lead at Pfizer (2019–2022), where the profile says the role led a global team of 17+ Site Intelligence Leads to ensure delivery of the right sites first time in clinical trials, and interim Director, Head of Global Site Intelligence (2021–2022).
Nicole Krupa, MPH
LinkedInExperience: Manager, Trial Feasibility & Site Identification · Daiichi Sankyo
Manager, Trial Feasibility & Site Identification at Daiichi Sankyo since September 2023. Former Principal, Global Feasibility (2021–2023), Senior Global Feasibility Lead (2021) and Data Science Lead (2020–2021) at Syneos Health, and Global Feasibility Lead II at Covance (2018–2020).
Nipa Patel
LinkedInExperience: Associate Director, Trial Feasibility & Site Intelligence · Daiichi Sankyo
Associate Director, Trial Feasibility & Site Intelligence at Daiichi Sankyo since January 2024, after serving as Trial Feasibility & Site Intelligence Manager there (2021–2024). Former Site Identification Manager (Operational Management) (2017–2021), Manager, Site ID (projects) (2014–2017) and Senior Feasibility and Site Specialist (2012–2014) at ICON plc.
Peter Glynn
LinkedInExperience: Senior Manager, Feasibility · Takeda
Senior Manager, Feasibility at Takeda since April 2026. Former Sr. Feasibility Analytics Manager for Johnson and Johnson Innovative Medicine at ICON plc (2022–2026) and Site Identification Specialist at PSI CRO (2020–2022) and ICON plc (2018–2020). The profile describes 10+ years leading clinical trial analytics, site identification and feasibility strategy.
Priscila Mattioli
LinkedInExperience: Development Feasibility Manager · Amgen
Development Feasibility Manager at Amgen since September 2023, where the profile describes leading country and site selection across Brazil and key LATAM countries including Argentina, Chile, Colombia, Peru and Mexico. Former Clinical Trial Manager at ICON plc (2015–2023) and clinical research coordinator roles at Takeda (2007–2015).
Stacy Eckstein, MS
LinkedInExperience: Senior Manager Global Site ID & Feasibility · Incyte
Senior Manager Global Site ID & Feasibility at Incyte since February 2025, after serving as Manager, Global Site ID & Feasibility (2023–2025) and Global Clinical Operations Lead (2019–2023) there. The profile describes developing site selection and feasibility strategies for in-house and outsourced studies using healthcare data from various platforms.
Choose the right perspective
Match the person's role to your question: feasibility leads and heads of feasibility strategy suit decisions on country mix and overall site strategy, while people who came up through site identification suit questions about site lists, outreach and data sources. Also weigh the therapeutic areas and regions they have worked in.
Questions to take into the conversation
- 01What data sources and criteria did you rely on to choose countries and sites, and which ones best predicted actual enrollment?
- 02How did you balance proven high-enrolling sites against new sites, including sites that could reach more diverse patient populations?
- 03When selected sites underperformed, how did you detect it early and decide whether to add or replace sites?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal